Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation

Pathology and Oncology Research - Netherlands
doi 10.1007/s12253-017-0255-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

MiR-34a Chemosensitizes Bladder Cancer Cells to Cisplatin Treatment Regardless of P53-Rb Pathway Status

International Journal of Cancer
Cancer ResearchOncology
2011English

1,25D3 Enhances Antitumor Activity of Gemcitabine and Cisplatin in Human Bladder Cancer Models

Cancer
Cancer ResearchOncology
2010English

The Molecular Basis of Cisplatin Resistance in Bladder Cancer Cells

2012English

Cisplatin and Gemcitabine With Either Vinorelbine or Paclitaxel in the Treatment of Carcinomas of Unknown Primary Site

Cancer
Cancer ResearchOncology
2006English

Cost-Effectiveness of Gemcitabine Plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced and or Metastatic Bilharzial Urothelial Carcinoma of the Bladder in Egypt.

Research in Oncology
2011English

Efficacy of Neoadjuvant Gemcitabine and Cisplatin in the Management of Muscle-Invasive Urothelial Carcinoma of the Bladder

Japanese Journal of Urology
Urology
2015English

TP53 Codon 72 Polymorphism Is Associated With FGFR3 and RAS Mutation in Non-Muscle-Invasive Bladder Cancer

PLoS ONE
Multidisciplinary
2019English

Sphingosine Induces Apoptosis and Down-Regulation of MYCN in PAX3–FOXO1-positive Alveolar Rhabdomyosarcoma Cells Irrespective of TP53 Mutation

Anticancer Research
MedicineCancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy